Browse drugs

…ineoplastic/immunomodulators) =2.9%. Drugs mainly involved were insulins (22.9%), benzodiazepines (20.0%), OAC (11.4%), opioids (8.6%), …

…t saving of €11,000 per patient when using Nivolumab instead of Pembrolizumab, with equivalent efficacy. This finding supports a review of pr…

…nt, and 43% worsening in perceived health status post-switch to Erelzi. Ten suspected adverse drug reactions were reported since IPC i…

…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…ortal outcome) as a suspected ADR of different ICIs (nivolumab, pembrolizumab and nivolumab+ipilimumab) within 2 months in the regional Pharm…

…0 (95% CI, 0.45-0.81; p=0.0009) between EV-Pembrolizumab versus Nivolumab-CT. According to the ATE guide, these treatments presented a degre…

…3-50.7); PFS=12.8 months (95% CI 6.6-18.8); ORR=not available]. Buparlisib plus fulvestrant presented the next best numerical efficacy [OS…

…ining exercises, and gut-directed hypnotherapy. Since App-based PDTx are not typical pharmaceutical agents; they may create complexi…

…tologic (lymphopenia), and serologic activity (SLEDAI-2K 6–8 on prednisolone 10 mg/day).Results In August 2024, anifrolumab 300 mg IV monthl…

… immunomodulation with combination targeted biologics—including eculizumab—may achieve full end-organ recovery despite life-threatening im…

…ximab, and plasmapheresis, followed by maintenance therapy with mycophenolate mofetil and voclosporin, can result in significant renal and pulmonary …